Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICE 1208
- Development stage
- Preclinical
- Lead developer
- Iroko Pharmaceuticals
- Modality
- Small Molecules
01
Overview
ICE 1208 is a preclinical-stage small molecule oncology candidate being developed by iCeutica for the treatment of leukemia. The drug utilizes iCeutica's proprietary SoluMatrix™ Fine Particle Technology, which is a dry milling process designed to reduce drug particles to sub-micron sizes. This reduction in particle size significantly increases the surface area of the drug, thereby enhancing the dissolution rate and bioavailability of poorly water-soluble compounds. ICE 1208 is currently in the early stages of development (Preclinical/Lead) and is listed as an asset available for partnering within iCeutica's oncology portfolio.
- Other names
- ICE 1208 LEUKEMIAICE1208 LEUKEMIAICE-1208 LEUKEMIA
Beyond the preview
Go deeper on ICE 1208.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICE 1208.